Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.49 |
| ▸ | GRIA4 | P48058 | 5/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.43 |
| ▸ | GRIA3 | P42263 | 4/20 | 0.43 |
| ▸ | NOS1 | P29475 | 3/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.39 |
| ▸ | ACE | P12821 | 3/20 | 0.39 |
| ▸ | ALPI | P09923 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5795113 | 1.00 | SLC1A3 (0.49) | SLC1A3GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL10397324 | 0.88 | SLC1A3 (0.47) | SLC1A3GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL10397323 | 0.88 | SLC1A3 (0.47) | SLC1A3GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL10398089 | 0.85 | SLC1A3 (0.44) | SLC1A3GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL10398088 | 0.85 | SLC1A3 (0.44) | SLC1A3GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL10769499 | 0.84 | SLC1A3 (0.49) | SLC1A3GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL18822326 | 0.84 | SLC1A3 (0.46) | SLC1A3GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL31295463 | 0.82 | ACE2 (0.37) | SLC1A3NOS1CYP3A4ACE2ACE | |
| SCHEMBL8824882 | 0.81 | SLC1A3 (0.51) | SLC1A3GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL28559 | 0.81 | SLC1A3 (0.51) | SLC1A3GRIA4GRIA1GRIA2GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4570017-A | Preparation of optically-active (mixed) anhydrides and acids | SHELL OIL COMPANY (US) | 1986-02-11 | — | — | US | claimed |
| US-4529810-A | Preparation of optically-active alpha-substituted carboxylic esters and acids | SHELL OIL COMPANY (US) | 1985-07-16 | — | — | US | claimed |
| EP-0116914-A1 | Preparation of optically-active alpha-substituted carboxylic esters and acids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-08-29 | — | — | EP | claimed |
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| WO-1996025155-A1 | DIAGNOSIS OF AND COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE | BIOSCREEN PTY. LIMITED (AU) | 1996-08-22 | — | — | WO | disclosed |
| WO-1992007872-A1 | TENASCIN RELATED PEPTIDES | CALIFORNIA INSTITUTE OF BIOLOGICAL RESEARCH (US) | 1992-05-14 | — | — | WO | disclosed |
| US-4570017-A | Preparation of optically-active (mixed) anhydrides and acids | SHELL OIL COMPANY (US) | 1986-02-11 | — | — | US | disclosed |
| US-4529810-A | Preparation of optically-active alpha-substituted carboxylic esters and acids | SHELL OIL COMPANY (US) | 1985-07-16 | — | — | US | disclosed |
| EP-0116914-A1 | Preparation of optically-active alpha-substituted carboxylic esters and acids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261950-A1 | Compounds that inhibit cholinesterase | ACHE, BCHE, CHAT | SLC1A3 1291/4885GRIA4 780/4885GRIA1 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.